LEGEND BIOTECH CORP-ADR (LEGN) Stock Analyst Ratings
USA - NASDAQ:LEGN - US52490G1022 - ADR
33.09 USD
+0.84 (+2.6%)
ChartMill assigns a Buy % Consensus number of 83% to LEGN. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 76.5. This target is 131.18% above the current price.
LEGN was analyzed by 25 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about LEGN.
In the previous month the buy percentage consensus was at a similar level.
LEGN was analyzed by 25 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-10-09 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-25 | JP Morgan | Maintains | Overweight -> Overweight |
| 2025-08-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-12 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-10 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-07-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-02 | UBS | Maintains | Buy -> Buy |
| 2025-05-14 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2025-05-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-22 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-03-12 | Guggenheim | Reiterate | Neutral -> Neutral |
| 2025-03-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-30 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-12-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-12-09 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-29 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-10-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-08 | Redburn Atlantic | Initiate | Buy |
| 2024-10-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
LEGEND BIOTECH CORP-ADR / LEGN FAQ
What is the price target for LEGN stock?
25 analysts have analysed LEGN and the average price target is 76.5 USD. This implies a price increase of 131.18% is expected in the next year compared to the current price of 33.09.
What is the consensus rating for LEGN stock?
The consensus rating for LEGEND BIOTECH CORP-ADR (LEGN) is 83.2 / 100 . This indicates that analysts generally have a positive outlook on the stock.
What is the number of analysts for LEGN stock?
The number of analysts covering LEGEND BIOTECH CORP-ADR (LEGN) is 25.